



(11) **EP 1 090 642 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 84

(51) Int Cl.:
A61K 39/385 ^(2006.01) **A61K 39/116** ^(2006.01)
A61K 39/295 ^(2006.01) **A61K 39/00** ^(2006.01)
A61P 31/00 ^(2006.01)

(48) Corrigendum issued on:
11.08.2010 Bulletin 2010/32

(45) Date of publication and mention
of the grant of the patent:
09.07.2008 Bulletin 2008/28

(21) Application number: **00203772.9**

(22) Date of filing: **04.06.1996**

(54) **Vaccines comprising a polysaccharide antigen-carrier protein conjugate and free carrier protein**
Vakzine mit einem Polysaccharide Antigen-Trägerprotein Konjugat und freiem Trägerprotein
Vaccins comprenant un conjugué antigénique de polysaccharideprotéine porteuse et une protéine porteuse libre

(84) Designated Contracting States:
**AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC
NL PT SE**
Designated Extension States:
SI

(30) Priority: **07.06.1995 US 472639**
23.06.1995 GB 9512827
01.07.1995 GB 9513443
15.12.1995 GB 9525657

(43) Date of publication of application:
11.04.2001 Bulletin 2001/15

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
96920790.1 / 0 831 901

(73) Proprietor: **GlaxoSmithKline Biologicals s.a.**
1330 Rixensart (BE)

(72) Inventors:
• **Slaoui, Moncef Mohamed,**
SmithKline Beecham Biol.SA
1330 Rixensart (BE)
• **Hauser, Pierre,**
SmithKline Beecham Biologicals S.A
1330 Rixensart (BE)

(74) Representative: **Privett, Kathryn Louise et al**
GlaxoSmithKline,
Corporate Intellectual Property (CN9.25.1),
980 Great West Road
Brentford, Middlesex TW8 9GS (GB)

(56) References cited:
EP-A- 0 208 375 EP-A- 0 594 950
US-A- 4 644 059

- **BARINGTON, T. ET AL.: "Opposite effects of actively and passively acquired immunity to the carrier on responses of human infants to a Haemophilus influenzae type b conjugate vaccine" INFECTION AND IMMUNITY, vol. 62, 1994, pages 9-14, XP000602292**
- **CORBEL, M.J.: "Control testing of combined vaccines: a consideration of potential problems and approaches" BIOLOGICALS, vol. 22, 1994, pages 353-360, XP000603003**
- **BÉGUÉ, P.: "Vaccins haemophilus influenzae" BULLETIN DE L'ACADÉMIE NATIONALE DE MÉDECINE, vol. 177, 1993, pages 1381-1387, XP000602905**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 1 090 642 B8

- | | |
|--|---|
| <ul style="list-style-type: none">• BARINGTON, T. ET AL.: "Non-epitope-specific suppression of the antibody response to Haemophilus influenzae type b conjugate vaccines by preimmunization with vaccine components" INFECTION AND IMMUNITY, vol. 61, 1993, pages 432-438, XP000602293 | <ul style="list-style-type: none">• FRASCH, C.E.: "Haemophilus influenzae type b conjugate and combination vaccines" CLINICAL IMMUNOTHERAPEUTICS, vol. 4, November 1995 (1995-11), pages 376-386, XP000602898 |
|--|---|